Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Toxicities and Off-Label Use of Cancer Drugs
Uncategorized

Toxicities and Off-Label Use of Cancer Drugs

By medwebJan 1, 2005
Share
Facebook Twitter Email

Toxicities and Off-Label Use of Cancer Drugs

By Elizabeth Crown

CHICAGO—Food and Drug Administration policies prevent pharmaceutical manufacturers from informing patients about potentially fatal toxicities that occur with some cancer drugs—policies that should be revised immediately, according to Northwestern University researchers.

Andrew M. Evens, DO, instructor in medicine, and Charles L. Bennett, MD, PhD, professor of medicine, at Northwestern University’s Feinberg School of Medicine, have called for an immediate revision of these FDA policies, particularly because the drug thalidomide, which was approved by the FDA as an off-label cancer treatment in 1998, has been reported to have caused potentially fatal blood clots in the legs and the lungs in more than 190 cancer patients.

Virtually all patients who have received thalidomide over the past six years have received the drug for cancer, making this drug the only one in the country whose use is exclusively off label.

The FDA strictly restricts discussion or dissemination of information to physicians and patients to “on label” indications, which prevents the pharmaceutical manufacturer from advising cancer patients about the side effects of thalidomide when it is used to treat cancer.

Moreover, despite an FDA mandate that all health care personnel and patients involved with thalidomide treatments participate in the preventive System for Thalidomide Education and Prescribing Safety, the program does not provide patients, pharmacists or health care providers with information on thromboembolisms.

Dr. Evens presented the Research on Adverse Drug Events and Reports (RADAR) data on the thalidomide-associated blood clots at the 46th Annual Meeting of the American Society of Hematology in early December.

The Northwestern study identified the occurrence of potential fatal blood clots in the legs and the lungs in up to 20 percent or more of cancer patients who received thalidomide.

The highest rates of thromboembolism occurred in patients who received concurrent treatment with thalidomide plus chemotherapy (18 percent) versus blood clots associated with thalidomide-corticosteroid combinations (13 percent) and single-drug treatment (5 percent).

Thalidomide, banned initially in 1962, has had a remarkable resurgence since 1998 for cancer, although its formal FDA approval is as a treatment of skin complication of the rare illness, leprosy.

“Given the current controversies about the FDA and pharmaceutical safety, our findings provide additional evidence that dramatic changes in the way the FDA address patient safety are needed,” Dr. Evens said.

Drs. Evens and Bennett are faculty physicians in the Department of Medicine, Division of Hematology/Oncology, at the Feinberg School and researchers at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The RADAR project, led by Dr. Bennett, is supported by a $5 million grant from the National Cancer Institute.

(Reprinted from the Northwestern University News Center.)

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Newly Discovered Mechanisms Increase Chemotherapy Resistance in Breast Cancer 

Jun 5, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.